9 results about "Recombinant glycoprotein" patented technology

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

The invention provides a recombinant glycoprotein trimer vaccine for preventing SFTS and application thereof, the vaccine comprises a recombinant Gn or Gc glycoprotein trimer, and the recombinant Gn or Gc glycoprotein trimer is composed of a Gn or Gc protein fragment and a corresponding trimer motif; the amino acid sequences of the Gn and Gc protein fragments are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and the motif of the trimer is T4, DMPK, MTQ, MTI, hCorla, Langerin, T3XV, MATN1 or CAT. Results show that the neutralizing antibody level induced by the Gn or Gc trimer is superior to that of a corresponding monomer or dimer, and the Gn or Gc trimer has higher cross-neutralization activity. Meanwhile, monomers and trimers of Gn or Gc can induce high-level Th1 and Th2 cytokines and antibody-dependent cytotoxic effect (ADCC) response. According to the invention, a dominant antigen structure which can more effectively stimulate the generation of the neutralizing antibody in the SFTSV is defined, and a new target spot and a new strategy are provided for enhancing immunogenicity in the research and development of the SFTSV vaccine.

The present application belongs to the field of microbial genetic engineering technology, and specifically relates to a Kluyveromyces marxianus engineering strain for improving the secretion and expression level of recombinant glycoprotein and application thereof. The engineering strain is obtained by using gene editing technology to introduce a human UGGT1, UGGT2, SEP15 and EDEM2 expression frame into Kluyveromyces marxianus based on FIM1DU as a starting strain, and introducing a point mutation into an endogenous alpha-glucosidase II beta subunit Gtb1. UGGT1 and UGGT2 are used to introduce a reglycosylation module, and UGGT1 and / or UGGT2 are further enhanced when used in combination with SEP15; the introduction of EDEM2 helps to reduce the degradation rate of intracellular glycoprotein; and the point mutation of Gtb1 can slow down the deglycosylation process. The strain constructed by the above single modification or combined modification can improve the expression and secretion level of the recombinant glycoprotein without affecting the biomass accumulation of the strain, indicating that the engineering strain has important application value for the production of recombinant glycoprotein.

The present invention relates to the field of expression of recombinant glycoproteins in plants. In particular, the present invention relates to a method of producing a genetically modified plant capable of producing glycoproteins harbouring paucimannosidic N-glycans, to a method of producing a glycoprotein of interest harbouring paucimannosidic N-glycans and to genetically modified plants, plant cells, protoplasts, protonemas, gametophytes, sporophytes or spores produced with or used in such methods.

The invention provides optimized processes for the production and purification of recombinant glycoprotein hormones, including recombinant human chorionic gonadotropin (r-hCG), recombinant human luteinizing hormone (r-hLH), recombinant follicle-stimulating hormone with extended half-life (FSH-CTP), and recombinant human follicle-stimulating hormone (r-hFSH). The processes employ sequential chromatography and filtration steps— affinity, hydrophobic interaction, ion exchange, mixed-mode, ultraf iltration / diaf iltration, nanofiltration, and final sterilizing filtration— with precisely controlled pH, conductivity, and buffer conditions. These strategies ensure robust viral clearance, high recovery yields, and effective removal of host cell proteins, DNA, aggregates, and other impurities, resulting in highly pure and stable drug substances. Analytical data from multiple batches confirm identity, consistency, and clinical suitability. The invention thus establishes a unified and scalable platform for large-scale manufacture of recombinant glycoprotein hormones for therapeutic use in fertility and reproductive healthcare.

The application discloses a recombinant glycoprotein targeting Siglec-9 and a preparation method and application thereof. The recombinant protein contains an amino acid sequence as shown in SEQ ID NO:1 or a sequence with more than 90% homology thereto. The recombinant protein targets and stimulates Siglec-9, serves as a Siglec-9 receptor stimulant, has strong binding force with Siglec-9, high activity, and has potential for treating excessive inflammatory diseases.

A method for vaccinating, immunizing, and / or treating a subject against herpes simplex virus infection or a disease caused by herpes simplex virus infection comprises administering to the subject an effective amount of HSV-2 short-cycle virus and an effective amount of recombinant HSV-2 glycoprotein D, wherein the HSV-2 short-cycle virus comprises HSV-2 having a deletion of the gene encoding glycoprotein D in its genome, and the HSV-2 is phenotypically complemented with HSV-1 glycoprotein D on the HSV-2 lipid bilayer.

The present disclosure relates to glycosylation engineering, including cells and methods for glycosylation engineering to engineer recombinant glycoproteins, whereby the glycoproteins produced bind to desired glycans.

An electrochemical detection method for detecting recombinant glycoprotein, comprising the following steps: A: preparing a phenylboronic acid-copper-based metal organic framework composite, comprising the following sub-steps: A1: synthesis of a copper-based metal organic framework; A2: preparation of a phenylboronic acid-copper-based metal organic framework composite; B: detection of the recombinant glycoprotein, comprising the following sub-steps: B1: resuspending nickel ion affinity magnetic beads in a phosphate buffer solution; B2: moving the dispersion prepared in step B1 into a microcentrifuge tube; B3: adding a to-be-detected substance containing the recombinant glycoprotein into the microcentrifuge tube; B4: dispersing the phenylboronic acid-copper-based metal organic framework composite obtained in step A2 in water and adding the solution obtained in step B3 to obtain a magnetic bead composite; B5: transferring the composite prepared in step B4 to the surface of a glassy carbon electrode; B6: soaking the electrode obtained in B5 in a Tris-HCl buffer solution, and the present application has low cost.